1 in 3 women and 1 in 5 men will suffer an osteoporotic fracture in their lifetime which is associated with significant mortality and morbidity. You and/or someone you know is likely affected by it, yet less than 25% of eligible patients are actually screened for it. Why? For many reasons: It's a silent disease, an overburdened system, it's an extra test to help prevent something in the distant future etc. Watch a video of our new product, Rho, an AI-driven opportunistic screening tool which uses already captured x-rays to assess someone's likelihood of having low bone mineral density.
Participating in GE's inaugural Canadian Edison AI Accelerator this year means that 16 Bit has the opportunity to deliver Rho along side Edison to future customers. We look forward to working with GE in the near future to distribute Rho widely and for the benefit of Canadians.